MANAGEMENT TEAM

Management Team

DANIEL J. O’CONNOR

CEO & DIRECTOR

Mr. O’Connor is the Chief Executive Officer of OncoSec Medical, Inc., a biopharmaceutical company developing intratumoral cancer immunotherapies

>> Read Full Bio

DANIEL J. O’CONNOR

×
Mr. O’Connor is the Chief Executive Officer of OncoSec Medical, Inc., a biopharmaceutical company developing intratumoral cancer immunotherapies.

Most recently, he served as President and Chief Executive Officer of Advaxis Inc., Mr. O’Connor successfully turned around the company, raising more than $300 million in funding and licensing deals, transforming it into a patient-focused, leading cancer immunotherapy company. He was also instrumental in establishing major partnerships with companies that include Amgen Inc., Merck & Co. and Bristol Myers Squibb. In addition, under his leadership, the company advanced four new cancer immunotherapy drug candidates into clinical trials, as well as several PD-1 combination clinical studies with Keytruda®* and Opdivo®*. Previously, Mr. O’Connor was Senior Vice President for ImClone Systems where he supported the clinical development, launch, and commercialization of ERBITUX®*, and the sale of the company to Eli Lilly in 2008. Mr. O’Connor served as General Counsel at PharmaNet (inventive Health) and was part of the senior leadership team that grew the company from a start-up contract research organization into a leader in clinical research.

Mr. O’Connor is a 1995 graduate of the Penn State University’s Dickinson School of Law in Carlisle, Pennsylvania and currently serves as an Entrepreneur Trusted Advisor to its Dean. He graduated from the United States Marines Corps Officer Candidate School in 1988 and was commissioned as an officer in the U.S. Marines, attaining the rank of Captain while serving in Saudi Arabia during Operation Desert Shield. Mr. O’Connor is currently the Vice Chairman of BioNJ and was a former New Jersey criminal prosecutor.

CHRISTOPHER G. TWITTY, PhD

CHIEF SCIENTIFIC OFFICER

Dr. Twitty brings over 20 years of experience in tumor immunology and cancer immunotherapy including the discovery and development of OncoSec’s leading clinical immune monitoring and biomarker program.

>> Read Full Bio

CHRISTOPHER G. TWITTY, PhD

×
Dr. Twitty brings over 20 years of experience in tumor immunology and cancer immunotherapy, including the discovery and development of OncoSec’s leading clinical immune monitoring and biomarker program.

Dr. Twitty earned his PhD from Oregon Health & Science University where his work was focused on novel tumor vaccine strategies and was awarded an American Cancer Society fellowship training grant for his post-doctoral studies in Dr. Bernard Fox’s Molecular Tumor Immunology Laboratory. After developing a pre-clinical and clinical immunological program focused on glioblastoma at Tocagen, Dr. Twitty joined Oncosec. Previously, Dr. Twitty held scientific positions of increasing responsibility at Bayer Pharmaceuticals and Cell Genesys, Inc.

ROBERT J. DELAVERSANO, C.P.A.

PRINCIPAL ACCOUNTING OFFICER AND CONTROLLER

Mr. DelAversano is a certified public account and has over fifteen years of experience in accounting including thirteen years in public accounting.

>> Read Full Bio

ROBERT J. DELAVERSANO, C.P.A.

×
Mr. DelAversano is a certified public account and has over fifteen years of experience in accounting including thirteen years in public accounting.

Prior to this appointment as OncoSec’s Principal Accounting Officer and Controller, Mr. DelAversano served as OncoSec’s Executive Director of Finance since 2018 where he had global responsibility for accounting, external financial reporting, and financial controls covering all aspects of OncoSec’s business. Prior to joining OncoSec, he was the Director of Financial Reporting and Taxation at Brio Financial Group (“Brio”), consulting with various public companies in financial reporting, internal control development and evaluation, budgeting and forecasting. Prior to joining Brio, Mr. DelAversano was a manager at Bartolomei Pucciarelli, LLC and oversaw their accounting and tax practice with industry focuses in manufacturing, wholesalers and medical devices services. In addition, he performed audit services, outsourced chief financial officer functions, and consulted clients through difficult Securities and Exchange Commission comment periods particularly through application of complex accounting principles for a large public company client base.

Mr. DelAversano holds a bachelor’s degree in Accounting from Rider University.

KELLIE MALLOY FOERTER

CHIEF CLINICAL DEVELOPMENT OFFICER

Ms. Malloy Foerter brings nearly thirty years of experience in clinical research with Syneos Health, inVentiv Health (previously PharmaNet), and Covance.

>> Read Full Bio

KELLIE MALLOY FOERTER

×
Ms. Malloy Foerter brings nearly thirty years of experience in clinical research with Syneos Health, inVentiv Health (previously PharmaNet), and Covance.

Prior to joining OncoSec Kellie served as Executive Vice President and General Manager, Clinical Solutions at Syneos Health. As a member of the Syneos Health Clinical executive leadership team, Ms. Malloy Foerter was responsible for the development and growth of multiple portfolios across therapeutic areas which included a strong focus on oncology and hematology trials, for the world’s leading biopharmaceutical companies. Earlier, Ms. Malloy Foerter spent 20 years at inVentiv Health (previously PharmaNet) where she held multiple positions of increasing responsibility, most recently serving as Senior Vice President, Clinical Research. Prior to inVentiv, she served as Senior Project Associate, Clinical Research Associate and Clinical Studies Assistant at Covance.

Ms. Malloy Foerter has a Bachelor of Science degree from Saint Joseph’s University in Philadelphia, PA.

KEIR LOIACONO

GENERAL COUNSEL, VICE PRESIDENT CORPORATE DEVELOPMENT, CHIEF COMPLIANCE OFFICER

Mr. Loiacono brings more than 17 years of success across the life sciences and medical device industries, having held commercial, legal and business roles.

>> Read Full Bio

KEIR LOIACONO

×
Mr. Loiacono brings more than 17 years of success across the life sciences and medical device industries, having held commercial, legal and business roles.

Mr. Loiacono draws on his extensive business, science and legal experience to head corporate development at OncoSec. Prior to joining OncoSec, Mr. Loiacono was the head of legal at Advaxis Inc., where he successfully negotiated and closed four strategic licensing transactions totaling approximately $75 million. Prior to Advaxis Keir spent 7 years in private practice as a licensed patent attorney with the Lerner David law firm. At Lerner David he specialized in transactions, as well as the monetization and management of IP portfolios for medical device and life science clients, including Fortune 500 companies, and successfully completed numerous transactions. Prior to practicing law, Keir was part of a launching sales force at OraPharma, Inc., which was later acquired by Johnson & Johnson, where he held positions of increasing responsibility in the commercial organization.

Mr. Loiacono hold a bachelor’s degree in biology (Cum laude) from Manhattan College and a Juris Doctorate from the Elisabeth Haub School of Law.

ROBERT W. ASHWORTH, PhD

SENIOR VICE PRESIDENT, REGULATORY QUALITY AND CMC

With more than 35 years of experience in the pharmaceutical industry, Dr. Ashworth is well-versed in drug development and global regulatory strategies and has made significant contributions to the FDA approval of 12 new drugs.

>> Read Full Bio

ROBERT W. ASHWORTH, PhD

×
With more than 35 years of experience in the pharmaceutical industry, Dr. Ashworth is well-versed in drug development and global regulatory strategies and has made significant contributions to the FDA approval of 12 new drugs.

Prior to joining OncoSec, Dr. Ashworth served as Vice President, Regulatory Affairs, Quality & Compliance for Advaxis, Inc., where he developed and executed the global regulatory strategy for the company’s immunotherapy platform and served as the company’s regulatory representative for clinical development programs involving Amgen, Bristol-Myers Squibb and Merck. Importantly, Dr. Ashworth was instrumental in securing a groundbreaking investigational new drug application (IND) for a personalized medicine, neo-epitope program. Before Advaxis, Dr. Ashworth was Vice-President, Global Regulatory Affairs at NPS Pharmaceuticals, Inc., where he built the company’s international regulatory department and was instrumental in negotiating the approval of NATPARA (PTH) for hypoparathyroidism. As Vice-President, Global Regulatory Affairs for Otsuka Pharmaceutical Development, Inc., Dr. Ashworth was responsible for the regulatory strategy for the company’s flagship product, ABILIFY®*. Dr. Ashworth’s career experience also includes regulatory positions at Biovail Corporation, Forest Laboratories, Inc., Knoll Pharmaceutical Company (BASF), and CIBA-Geigy Corporation.

Dr. Ashworth earned a B.S. in Chemistry from St. John’s University and his Ph.D. in Organic Chemistry from MIT.

JOHN RODRIGUEZ

VICE PRESIDENT, PRODUCT ENGINEERING

Mr. Rodriguez is a leader in product development with over 30 years of experience heading teams in the design, development and manufacture of products for the biomedical industry.

>> Read Full Bio

JOHN RODRIGUEZ

×
Mr. Rodriguez is a leader in product development with over 30 years of experience heading teams in the design, development and manufacture of products for the biomedical industry.

Prior to joining OncoSec, Mr. Rodriguez served as Senior Director of Product Development for Cytori Therapeutics, where he was responsible for the development of Cytori’s stem and regenerative cell products. Mr. Rodriguez biomedical product manufacturing experience includes both domestic and OUS manufacturing with specific experience in Europe, South America and Asia.

Mr. Rodriguez has held positions of increasing responsibility in the biomedical and product development fields since beginning his career at Johnson & Johnson Medical Inc in 1987. In addition to Mr. Rodriguez relevant immunotherapy and oncology experience with electroporation product at both Inovio Biomedical and Genetronics, Mr. Rodriguez tenure includes development of product with Advanced Sterilization Products, Gynecare, Ethicon Endo-Surgery and Ethicon Inc.

Mr. Rodriguez has a bachelor’s degree in Manufacturing Engineering from National University, and a degree in Executive Perspective for Scientists and Engineers from the University of California, San Diego.

KIM JAFFE, PhD

SENIOR DIRECTOR, OPERATIONS

Dr. Jaffe brings nearly 20 years of experience in both academia and industry to OncoSec.

>> Read Full Bio

KIM JAFFE, PhD

×
Dr. Jaffe brings nearly 20 years of experience in both academia and industry to OncoSec.

As Senior Director of Operations, Dr. Jaffe translates her extensive science experience as a backdrop for business development, operational management, and corporate strategy. She oversees numerous programs, including our CAR-T collaboration with the Marasco lab at DFCI, Emerge Health SAS program for TAVO in Australia, and our new visceral lesion applicator (VLA) platform. She is also extensively involved with search and evaluation and identifying new partnering opportunities. Prior to OncoSec, Dr. Jaffe held various positions of increasing responsibility, including Director of Research, at several private and public biotech companies in the oncology sector. In addition to her research roles, she has broad experience interacting with U.S. and European regulatory authorities and has overseen the development and manufacturing operations of a neoantigen-based immuno-oncology platform. Dr. Jaffe earned her PhD in Molecular and Cell Biology from Northwestern University and performed her post-doctoral research at Princeton University.

Board of Directors

DANIEL J. O’CONNOR

CEO & DIRECTOR

Mr. O’Connor is the Chief Executive Officer of OncoSec Medical, Inc., a biopharmaceutical company developing intratumoral cancer immunotherapies.

>> Read Full Bio

DANIEL J. O’CONNOR

×
Mr. O’Connor is the Chief Executive Officer of OncoSec Medical, Inc., a biopharmaceutical company developing intratumoral cancer immunotherapies.
Most recently, he served as President and Chief Executive Officer of Advaxis Inc.,

Mr. O’Connor successfully turned around the company, raising more than $300 million in funding and licensing deals, transforming it into a patient-focused, leading cancer immunotherapy company. He was also instrumental in establishing major partnerships with companies that include Amgen Inc., Merck & Co. and Bristol Myers Squibb. In addition, under his leadership, the company advanced four new cancer immunotherapy drug candidates into clinical trials, as well as several PD-1 combination clinical studies with Keytruda®* and Opdivo®*. Previously, Mr. O’Connor was Senior Vice President for ImClone Systems where he supported the clinical development, launch, and commercialization of ERBITUX®*, and the sale of the company to Eli Lilly in 2008. Mr. O’Connor served as General Counsel at PharmaNet (inventive Health) and was part of the senior leadership team that grew the company from a start-up contract research organization into a leader in clinical research.

Mr. O’Connor is a 1995 graduate of the Penn State University’s Dickinson School of Law in Carlisle, Pennsylvania and currently serves as an Entrepreneur Trusted Advisor to its Dean. He graduated from the United States Marines Corps Officer Candidate School in 1988 and was commissioned as an officer in the U.S. Marines, attaining the rank of Captain while serving in Saudi Arabia during Operation Desert Shield. Mr. O’Connor is currently the Vice Chairman of BioNJ and was a former New Jersey criminal prosecutor.

AVTAR DHILLON, M.D.

CO-FOUNDER / CHAIRMAN

Founder of OncoSec Medical, Inc. and Vitality Biopharma, Inc., Avtar S. Dhillon is a businessperson who has been the head of 9 different companies.

>> Read Full Bio

AVTAR DHILLON, M.D.

×
Founder of OncoSec Medical, Inc. and Vitality Biopharma, Inc., Avtar S. Dhillon is a businessperson who has been the head of 9 different companies.

Dr. Dhillon holds the position of Non-Executive Chairman for OncoSec Medical, Inc., Executive Chairman & President at Emerald Health Pharmaceuticals, Inc., Chairman, President & Chief Executive Officer at Emerald Health Sciences, Inc., Chairman for Nemus Bioscience, Inc. and Executive Chairman & President at Emerald Health Therapeutics, Inc. Dr. Dhillon is also on the board of Arch Biosurgery, Inc., Cannabis Canada Association and Emerald Health Bioceuticals, Inc. and Member of Canadian Medical Association, Member of College of Physicians & Surgeons of BC and Member of College of Family Practitioners.

He previously was Chairman at Vitality Biopharma, Inc., Non-Executive Chairman of Inovio Pharmaceuticals, Inc. and President & Chief Executive Officer at Genetronics Biomedical Corp. (a subsidiary of Inovio Pharmaceuticals, Inc.), Chairman for Arch Therapeutics, Inc., Member of Doctors of BC and Vice President & Investment Manager at Lumira Capital Investment Management, Inc.

Dr. Dhillon received a doctorate and an undergraduate degree from the University of British Columbia.

al in establishing major partnerships with companies that include Amgen Inc., Merck & Co. and Bristol Myers Squibb. In addition, under his leadership, the company advanced four new cancer immunotherapy drug candidates into clinical trials, as well as several PD-1 combination clinical studies with Keytruda®* and Opdivo®*. Previously, Mr. O’Connor was Senior Vice President for ImClone Systems where he supported the clinical development, launch, and commercialization of ERBITUX®*, and the sale of the company to Eli Lilly in 2008. Mr. O’Connor served as General Counsel at PharmaNet (inventive Health) and was part of the senior leadership team that grew the company from a start-up contract research organization into a leader in clinical research.

Mr. O’Connor is a 1995 graduate of the Penn State University’s Dickinson School of Law in Carlisle, Pennsylvania and currently serves as an Entrepreneur Trusted Advisor to its Dean. He graduated from the United States Marines Corps Officer Candidate School in 1988 and was commissioned as an officer in the U.S. Marines, attaining the rank of Captain while serving in Saudi Arabia during Operation Desert Shield. Mr. O’Connor is currently the Vice Chairman of BioNJ and was a former New Jersey criminal prosecutor.

ROBERT E. WARD

DIRECTOR

Mr. Ward is currently the Chief Executive Officer and Chairman of the Board of Eloxx Pharmaceuticals, Inc., roles he has held since December 2017. He was a Director and Chair of the Governance Committee of Akari Therapeutics from October 2016 to August 2018.

>> Read Full Bio

ROBERT E. WARD

×
Mr. Ward is currently the Chief Executive Officer and Chairman of the Board of Eloxx Pharmaceuticals, Inc., roles he has held since December 2017. He was a Director and Chair of the Governance Committee of Akari Therapeutics from October 2016 to August 2018.

Mr. Ward previously served as the Chief Executive Officer, President and member of the board of directors at Radius Health, Inc. from December 2013 to July 2017. Prior to joining Radius, Mr. Ward was Vice President for Strategy and External Alliances for the New Opportunities iMed of AstraZeneca from 2011 to December 2013. He has held a series of progressive management and executive roles with established companies such as NPS Pharmaceuticals, Schering-Plough (Merck), Pharmacia (Pfizer), Bristol-Myers Squibb and Genentech. Mr. Ward has been a Director of Akari Therapeutics, Plc since October 2016. Mr. Ward received a B.A. in Biology and a B.S. in Physiological Psychology, both from the University of California, Santa Barbara, a M.S. in Management from the New Jersey Institute of Technology and an M.A. in Immunology from The Johns Hopkins University School of Medicine. Mr. Ward’s extensive experience and expertise in the biopharmaceuticals industry are the primary qualifications the Board considered in nominating him as a director of the Company.

MARGARET R. DALESANDRO, PhD

DIRECTOR

Dr. Dalesandro brings more than 25 years of drug development experience in the pharmaceutical, biotechnology and diagnostics industries.

>> Read Full Bio

MARGARET R. DALESANDRO, PhD

×
Dr. Dalesandro brings more than 25 years of drug development experience in the pharmaceutical, biotechnology and diagnostics industries.

She currently serves as the President of Brecon Pharma Consulting, a full-service pharmaceutical and biotech consultancy firm. She previously served as Business Director of Corning Integrative Pharmacology. Before that, Dr. Dalesandro held an executive leadership role at ImClone Systems where she oversaw project management for the clinical development of ERBITUX® (cetuximab), making significant contributions to the sale of ImClone to Eli Lilly in 2008. Prior to that, Dr. Dalesandro served as an Executive Director at GlaxoSmithKline, managing cardiovascular, urology, and oncology drug product commercialization. Earlier in her career, she was a senior consultant at Cambridge Pharma Consultancy and a Director of Immunobiology and Diagnostic Research at Centocor.

Dr. Dalesandro holds a Ph.D. and M.A. in Biochemistry from Bryn Mawr College and an A.B. in Biology and Chemistry from Rosemont College, where she graduated summa cum laude.

CHAO ZHOU

DIRECTOR

Chao Zhou is currently the Executive Deputy Officer of China Grand Pharmaceutical and Healthcare Holdings Limited, a public company listed on the Hong Kong stock exchange.

>> Read Full Bio

CHAO ZHOU

×
Chao Zhou is currently the Executive Deputy Officer of China Grand Pharmaceutical and Healthcare Holdings Limited, a public company listed on the Hong Kong stock exchange that develops, manufactures and distributes pharmaceutical products and medical devices to retailers and medical organizations with significant experience in R&D and product commercialization in China.

Since 2018, Mr. Zhou has served on the Board of Directors of Grand Pharma Sphere Pty Ltd, a Singapore based company that indirectly wholly-owns the Australian based global medical device company, Sirtex Medical Pty. Ltd. Prior to his role as Executive Deputy Officer, Mr. Zhou served as a Management Director in the Department of Legal Security for China Grand Enterprises, Inc., an investment company engaged in the operation and management of businesses covering pharmaceuticals and healthcare, commodity trading, real estate investment, financial service and other sectors. He earned his Bachelor in Law from Ocean University of China and a Master in International Law from the University of International Business and Economics.

KEVIN R. SMITH

DIRECTOR

Kevin R. Smith is currently the Chief Executive Officer of Sirtex Medical US Holdings, Inc. He combines more than 20 years of sales and marketing experience in the medical device industry with the keen instincts of an entrepreneur.

>> Read Full Bio

KEVIN R. SMITH

×
Kevin R. Smith is currently the Chief Executive Officer of Sirtex Medical US Holdings, Inc. He combines more than 20 years of sales and marketing experience in the medical device industry with the keen instincts of an entrepreneur.

Prior to his appointment to CEO, Mr. Smith was Executive Vice President of Sales & Marketing, Americas. Before joining Sirtex, Mr. Smith was Executive Vice President of Business Development at Gel-e, Inc., a company based at the University of Maryland specializing in advanced material hemostasis products. His previous positions include Chief Commercial Officer of Sensium Healthcare along with Global Vice President of Sales & Marketing at Teleflex, where he was the senior sales and marketing executive in the company’s cardiac business unit. Kevin holds a Master of Business Administration in Global Management from the University of Phoenix and a Bachelor of Science in Marketing from the University of Kentucky.

JIM DEMESA, MD, MBA

DIRECTOR

Dr. DeMesa has served as a senior executive with several international pharmaceutical and biotech companies in the areas of corporate management, regulatory affairs, and pre-clinical and clinical pharmaceutical and medical device product development.

>> Read Full Bio

JIM DEMESA, MD, MBA

×
Dr. DeMesa has served as a senior executive with several international pharmaceutical and biotech companies in the areas of corporate management, regulatory affairs, and pre-clinical and clinical pharmaceutical and medical device product development.

Most recently, Dr. DeMesa served as President, CEO, and Director of Migenix Inc., a public biotechnology company. Dr. DeMesa was also president, CEO and Director of GenSci Regeneration Sciences Inc., a public biotech company, Vice President of Medical and Regulatory Affairs at Biodynamics International, Inc., and Vice President of Medical and Regulatory Affairs at Bentley Pharmaceuticals. He has been a practicing physician and is a Co-Founder of CommGeniX, a medical communications company, and MedXcel, a medical education company.

YUHANG ZHAO, PhD, MBA

DIRECTOR

Dr. Yuhang Zhao, a graduate from Peking University, received her Doctorate in Molecular Biology from Rockefeller University and her MBA in Finance from NYU Stern Business School.

>> Read Full Bio

YUHANG ZHAO, PhD, MBA

×
Dr. Yuhang Zhao, a graduate from Peking University, received her Doctorate in Molecular Biology from Rockefeller University and her MBA in Finance from NYU Stern Business School.

Dr. Zhao was most recently a member of the Bayer Global Leadership Circle. She established one of Bayer’s four Global Clinical Development sites, located in Beijing, China in 2009. She then became Head of Global Strategy for Bayer Consumer Health, reporting to the President. Prior to her positions in the pharmaceutical industry, Dr. Zhao held positions as a stock analyst at PaineWebber and was a management consultant specializing in strategies for life science companies. Dr. Zhao currently serves on the board of R2 Technologies and is a senior adviser to China Grand Enterprises.

JOON KIM

DIRECTOR

Joon Kim is a highly accomplished attorney and partner in Lee & Ko’s Corporate, International Litigation and Dispute Resolution, and White Collar Crime Practice Groups. Mr. Kim advises clients, both domestic and international, on a broad range of litigation, dispute-resolution and transactional matters.

>> Read Full Bio

JOON KIM

×
Joon Kim is a highly accomplished attorney and partner in Lee & Ko’s Corporate, International Litigation and Dispute Resolution, and White Collar Crime Practice Groups. Mr. Kim advises clients, both domestic and international, on a broad range of litigation, dispute-resolution and transactional matters.

With a particularly strong background in representing clients in court proceedings, Mr. Kim has a comprehensive understanding of every stage of the litigation process, including all aspects of initial investigatory/discovery proceedings, settlement negotiations, hearings, motions, trials, evidentiary issues and the handling of post-judgment challenges and appeals.

Prior to joining Lee & Ko, Mr. Kim worked for several years as a litigation lawyer and served from 2008 to 2017 as a public prosecutor in California. Mr. Kim has first-chaired both jury and non-jury trials, and has been trained in all aspects of litigation. During his time as a public prosecutor, Mr. Kim also had the experience of serving in 2016 as a research fellow in Korea at the Institute of Justice, under the auspices of the Korea Ministry of Justice, where he worked together with Korean public prosecutors. Joon received his J.D. from Berkeley School of Law and his B.S. from the Berkeley School of Business.

Scientific Advisory Board

RICHARD HELLER, PHD

Dr. Heller has over 25 years of experience in evaluating effects of electric pulses on biological systems. He is recognized as a pioneer on the use of electrotransfer for drug and gene delivery.

>> Read Full Bio

RICHARD HELLER, PHD

×
Dr. Heller has over 25 years of experience in evaluating effects of electric pulses on biological systems. He is recognized as a pioneer on the use of electrotransfer for drug and gene delivery.

His research group has developed new protocols or devices that are being tested for potential therapies for cancer, wound healing and vascular diseases (peripheral or coronary ischemia) as well as vaccine and immunotherapy protocols. His work in this gene therapy approach was translated into the clinic and represents the first-in-human study utilizing in vivo gene electrotransfer of a plasmid. Richard Heller is currently Director of the Frank Reidy Research Center for Bioelectrics (CBE) and Professor in the School of Medical Diagnostics and Translational Sciences in the College of Health Sciences at Old Dominion University (ODU).

IACOB MATHIESEN, PHD

Dr. Mathiesen has a PhD from University of Oslo, Norway. He was a co-founder of Inovio AS, Norway and inventor on numerous electroporation related patents covering devices and methods for gene based immune therapy.

>> Read Full Bio

IACOB MATHIESEN, PHD

×
Dr. Mathiesen has a PhD from University of Oslo, Norway. He was a co-founder of Inovio AS, Norway and inventor on numerous electroporation related patents covering devices and methods for gene based immune therapy.

After Inovio AS was acquired by Genetronics Biomedical in 2005 (now Inovio Pharmaceuticals), IM was director of gene delivery at Inovio in San Diego. Iacob has more than 10 years’ experience with IP, electroporation devices and methods and worked closely with University of Southampton to initiate the first human clinical trial using electroporation do delivery a gene based vaccine. Iacob is currently CEO of Otivio AS in Norway, a new startup developing methods and devices for wound healing and temperature management.

SOLDANO FERRONE, MD, PHD

Dr. Ferrone leads a research program focused on the characterization of escape mechanisms deployed by tumor cells to avoid immune-mediated recognition and destruction.

>> Read Full Bio

SOLDANO FERRONE, MD, PHD

×
Dr. Ferrone leads a research program focused on the characterization of escape mechanisms deployed by tumor cells to avoid immune-mediated recognition and destruction.

He has also studied how combined immunotherapeutic strategies can counteract these tumor escape mechanisms. These studies are greatly facilitated by the large panel of HLA antigen- and human tumor antigen-specific monoclonal antibodies he has developed and shared with the scientific community over the years.

Dr. Ferrone received his M.D. and Ph.D. degrees in 1964 and in 1971, respectively, from the University of Milan, in Milan, Italy. He has held faculty positions at the University of Milan; Scripps Clinic and Research Foundation, La Jolla, CA; Columbia University, New York, NY; New York Medical College, Valhalla, NY; Roswell Park Cancer Institute, Buffalo, NY; and University of Pittsburgh School of Medicine, Pittsburgh, PA. He was recently appointed Professor in Residence of Surgery at Massachusetts General Hospital, Harvard Medical School, in Boston, MA. For the last 30 years, he has been a member of many review committees including NIH Study Sections, and editorial boards of many scientific journals. Furthermore, he is a member of several external scientific advisory boards.

Dr. Ferrone has received numerous awards and honors. He has described the results of his studies in more than 600 papers published in peer-reviewed journals. Moreover, he has been the editor of 14 books and the guest editor of five special issues of oncology journals.

Clinical Advisory Board

ALAIN ALGAZI M.D.

Associate Professor, Department of Medicine (Hematology / Oncology), UCSF Program Leader, UCSF Head and Neck Medical Oncology Melanoma Specialist, UCSH Medical Center

ROBERT H.I. ANDTBACKA, M.D., CM, FACS, FRCSC

Associate Professor, Surgical Oncology Department of Surgery University of Utah, Co-Director Melanoma Program, Co-Director Melanoma Clinical Research Program Huntsman Cancer Institute

AXEL HAUSCHILD, M.D.,Ph.D

Professor of Dermatology, Department of Dermatology, University Hospital Schleswig-Holstein in Kiel, Germany

GEORGINA LONG, BSc, Ph.D., MBBS, FRACP

Conjoint Medical Director Melanoma Institute Australia, Professor of Melanoma Medical Oncology and Translational Research Melanoma Institute Australia, University of Sydney, Royal North Shore Hospital

PAMELA MUNSTER, M.D.

Professor, Department of Medicine (Hematology/Oncology), UCSF; Director, Early Phase Clinical Trials Unit, Co-leader of the Center for BRCA Research, and Leader, Experimental Therapeutics Program, UCSF Helen Diller Family Comprehensive Cancer Center

WALTER J URBA, M.D., Ph.D.

Medical Oncologist; director of cancer research; co-director, Providence Melanoma Programy